SCHEMBL19852527

SCHEMBL19852527

CC(C)(C)OC(=O)N1CCCCC(O)CCC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.62
EPHX1 P07099 1/20 0.55
USP2 O75604 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
MAPT P10636 2/20 0.49
ALDH1A1 P00352 1/20 0.49
PREP P48147 2/20 0.49
RECQL P46063 1/20 0.48
CHRM2 P08172 1/20 0.47
CHRM1 P11229 1/20 0.47
CHRM3 P20309 1/20 0.47
ABL1 P00519 1/20 0.46
RIN1 Q13671 1/20 0.46
GPR119 Q8TDV5 2/20 0.44
HSD17B10 Q99714 1/20 0.43
KDM4E B2RXH2 1/20 0.43
THRB P10828 1/20 0.43
PTPN2 P17706 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21183487 0.98 HPGD (0.64) HPGDEPHX1USP2SMN1; SMN2MEN1
SCHEMBL21142470 0.97 HPGD (0.67) HPGDEPHX1USP2SMN1; SMN2MEN1
SCHEMBL23946114 0.96 HPGD (0.61) HPGDEPHX1USP2SMN1; SMN2MEN1
SCHEMBL13779779 0.93 HPGD (0.62) HPGDEPHX1USP2SMN1; SMN2MEN1
SCHEMBL15107851 0.93 HPGD (0.62) HPGDEPHX1USP2SMN1; SMN2MEN1
SCHEMBL1096914 0.93 HPGD (0.62) HPGDEPHX1USP2SMN1; SMN2MEN1
SCHEMBL2820898 0.88 HPGD (0.56) HPGDEPHX1USP2SMN1; SMN2MEN1
SCHEMBL24438917 0.88 HPGD (0.56) HPGDEPHX1USP2SMN1; SMN2MEN1
SCHEMBL22439376 0.88 HPGD (0.56) HPGDEPHX1USP2SMN1; SMN2MEN1
SCHEMBL31045798 0.87 HPGD (0.59) HPGDEPHX1USP2SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11685729-B2 C5a receptor modulators IDORSIA PHARMACEUTICALS LTD. (CH) 2023-06-27 US disclosed
US-20210122736-A1 C5A RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD. (CH) 2021-04-29 US disclosed
WO-2018026371-A1 DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210122736-A1 C5A RECEPTOR MODULATORS C5AR1, C3AR1, C5AR2 HPGD 2541/4885EPHX1 1256/4885USP2 4032/4885
US-11685729-B2 C5a receptor modulators C5AR1, C3AR1, C5AR2 HPGD 2541/4885EPHX1 1256/4885USP2 4032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.